Swiss pharma group Roche reported an increase in their global sales in the first half of the year by 5 percent, at a constant exchange rate, reaching CHF 22.9 billion due to the increased demand for cancer and autoimmune drugs, reports a press relese. According to Severin Schwan, Roche CEO, the good results are due to the performance of the cancer drugs, especially those against breast cancer, and the diagnostic division. The R&D division reported major progress as well both in Pharma and Diagnostic areas. )…) Considering the performance of Roche Group over the first six months, I am sure we will meet our targets for 2014,” stressed Schwan. For the current year, Roche forecasts an increase in sales of about 5 percent, for a constant exchange rate and higher dividends.